A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma
These findings uncover a novel TK-IMPDH2 signaling axis and provide mechanistic and therapeutic insight into the allosteric regulation of IMPDH2. Comp-10 represents a promising therapeutic candidate for targeting metabolic vulnerabilities in tyrosine kinase driven cancers.
Authors
- Nagarajan Pattabiraman
- Cosimo Lobello (ORCID: https://orcid.org/0000-0003-1329-2113)
- Luca Mologni (ORCID: https://orcid.org/0000-0002-6365-5149)
- Johnvesly Basappa (ORCID: https://orcid.org/0009-0009-0907-3541)
- Mariusz Wasik
- David Rushmore
Institutions
- Fox Chase Cancer Center (US)
- Versar (United States) (US)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3390/cancers17203389
- Primary Topic
- Biochemical and Molecular Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Pennsylvania